Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Setmelanotide on QTc Interval in Healthy Subjects
NCT05046132Phase 4Completed
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Aug 2021
- Primary completion
- Apr 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of setmelanotide in obesity (3 arms), sponsored by Rhythm Pharmaceuticals. Primary endpoint: Setmelanotide Concentration-related Placebo-corrected Change From Baseline in Fridericia's Correction (QTcF) at Day 16. Started Aug 2021; status: completed.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05046132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05046132.